Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Articles
Value-Based Insurance Not Such an Easy Sell
Read More
What Makes a Treatment Clinically Meaningful?
Read More
ASCO Beginning to Address Value in Oncology
Read More
Lung Cancer
,
Oncology
Ramucirumab Shows Survival Benefit in NSCLC
Read More
Federal Spending on Cancer Research and Access to Care Woefully Inadequate
Read More
FDA Approvals
Anti–PD-1 Antibodies for NSCLC and Renal Carcinoma
Read More
Prostate Cancer
Upfront Docetaxel Markedly Improves Survival in Metastatic Prostate Cancer, at Reduced Cost
Read More
FDA Approvals
Enthusiasm Sky High for Immunotherapy with Anti–PD-1 Agents in Cancer
Read More
Generic Docetaxel Increases Risk of Neutropenia, Costs
Read More
Financial Distress Experienced by 40% of Patients with Cancer
Read More
144
145
146
147
148
149
150
Page 147 of 244
Results 1461 - 1470 of 2434
